Real World Experience of Anakinra for the Treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell Lymphoma

Key Points

• Anakinra leads to improved outcomes in immune effector cell-associated neurotoxicity syndrome.
• Among the 15 patients treated, significant reductions in clinical symptoms were observed from baseline to treatment.
• The analysis integrates clinical data from multiple treatment centers, emphasizing real-world effectiveness of the intervention.
• Further validation in larger trials is necessary to confirm these findings in diverse patient populations.